Aclarion, Inc., a leader in healthcare technology focused on chronic low back pain diagnostics, has announced a registered direct offering of its common stock, aiming to raise approximately $4.7 million. The offering involves the sale of 506,803 shares at $9.25 each, with the transaction expected to close around January 31, 2025. This financial move is designed to bolster the company's strategic initiatives, including market development, clinical evidence generation, product development, and quality enhancement efforts.
The Nociscan platform, Aclarion's flagship innovation, leverages Magnetic Resonance Spectroscopy, proprietary signal processing, and augmented intelligence to analyze chemical biomarkers from MRI data. This technology provides physicians with unprecedented insights into the sources of chronic low back pain, potentially revolutionizing treatment strategies. The platform's cloud-based software represents a significant leap forward in diagnostic capabilities, offering hope for millions suffering from this pervasive condition.
Dawson James Securities, Inc. is acting as the sole placement agent for this offering, which is being conducted under a shelf registration statement effective as of September 23, 2024, by the Securities and Exchange Commission. Aclarion has made it clear that the press release does not serve as an offer to sell securities, directing potential investors to the prospectus supplement for detailed information and risk assessment.
This funding initiative underscores Aclarion's commitment to advancing healthcare technology and improving patient outcomes. By channeling resources into the Nociscan platform's development and market expansion, the company is poised to make a lasting impact on the diagnosis and treatment of chronic low back pain. For more information on Aclarion and its innovative solutions, visit https://www.aclarion.com.
